Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov 3:3:25-30.

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Ariane Höer  1 , Cornelia Seidlitz, Holger Gothe, Guido Schiffhorst, Melvin Olson, Peyman Hadji, Bertram Häussler
Affiliations

Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis

Ariane Höer et al. Patient Prefer Adherence. .

Abstract

Background and aim: Oral bisphosphonates have been shown to reduce the risk of fractures in patients with osteoporosis. It can be assumed that the clinical effectiveness of oral bisphosphonates depends on persistence with therapy.

Methods: The influence of persistence with and adherence to oral bisphosphonates on fracture risk in a real-life setting was investigated. Data from 4451 patients with a defined index prescription of bisphosphonates were included. Fracture rates within 180, 360, and 720 days after index prescription were compared between persistent and non-persistent patients. In an extended Cox regression model applying multiple event analysis, the influence of adherence was analyzed. Persistence was defined as the duration of continuous therapy; adherence was measured in terms of the medication possession ratio (MPR).

Results: In patients with a fracture before index prescription, fracture rates were reduced by 29% (p = 0.025) comparing persistent and non-persistent patients within 180 days after the index prescription and by 45% (p < 0.001) within 360 days. The extended Cox regression model showed that good adherence (MPR >/= 0.8) reduced fracture risk by about 39% (HR 0.61, 95% CI 0.47-0.78; p < 0.01).

Conclusions: In patients with osteoporosis-related fractures, good persistence and adherence to oral bisphosphonates reduced fracture risk significantly.

Keywords: compliance; fracture risk; oral bisphosphonates; persistence.

PubMed Disclaimer

References

    1. List of National and Regional Osteoporosis Guidelines International Osteoporosis Foundation. Available from: http://www.iofbonehealth.org/health-professionals/national-regional-guid... (Accessed December 04, 2007).
    1. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ. 2002;166:1426–1430. - PMC - PubMed
    1. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287. - PubMed
    1. Penning-van Beest FJA, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511–517. - PMC - PubMed
    1. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003–1008. - PubMed

LinkOut - more resources